Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells

Drug Metabolism and Disposition

Volumn 24, Issue 6, 1996, Pages 634-642

  Prueksaritanont, Thomayant ^a   Gorham, Lynn M ^a   Hochman, Jerome H ^a   Tran, Lekhanh O ^a   Vyas, Kamlesh P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; BUFURALOL; CARBOXYLESTERASE; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; ETHOXYRESORUFIN; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; INTESTINE ENZYME; MICROSOME ENZYME; PARACETAMOL; SULFOTRANSFERASE; TOLBUTAMIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; DOG; DRUG METABOLISM; DRUG SULFATION; ENZYME ACTIVITY; ENZYME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MONKEY; NONHUMAN; PRIORITY JOURNAL; SMALL INTESTINE; SPECIES DIFFERENCE;

ADULT; AGED; ANIMALS; CACO-2 CELLS; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; HUMANS; INTESTINE, SMALL; MACACA MULATTA; MALE; MICROSOMES, LIVER; MIDDLE AGED; SPECIES SPECIFICITY; STEROID HYDROXYLASES;

EID: 0029998275     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. D. R. Krishma and U. Klotz: Extrahepatic metabolism of drugs in humans. Clin. Pharmacokinet. 26, 144-160 (1994).
2. I. de Waziers, P. H. Cugnenc, C. S. Yang, J.-P. Leroux, and P. H. Beaune: Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J. Pharmacol. Exp. Ther. 253, 387-394 (1990).
3. L. S. Kaminsky: Small intestinal cytochromes P-450. Toxicology 21, 407-422 (1992).
4. 14C]1,3-dinitrobenzene by rat small intestinal mucosa in vitro. Drug Metab. Dispos. 23, 982-987 (1995).
5. F. P. Guengerich and T. Shimada: Human cytochrome P450 enzymes and chemical carcinogenesis. In "Human Drug Metabolism" (E. H. Jeffery, ed.), pp. 5-21. CRC Press, Ann Arbor, 1993.
6. D. J. Back, M. Bates, A. M. Breckenridge, A. Ellis, J. M. Hall, M. Maciver, M. L., E. Orme, and P. H. Rowe: The in vitro metabolism of ethinyloestradiol, mestranol and levonorgestel by human jejunal mucosa. Br. J. Clin. Pharmacol. 11, 275-278 (1981).
7. G. M. Pacifici, M. Eligi, and L. Giuliani: (+) and (-) terbutaline are sulphated at a higher rate in human intestine than in liver. Eur. J. Clin. Pharmacol. 45, 483-487 (1993).
8. J. C. Kolars, W. M. Awni, R. M. Merion, and P. B. Watkins: First-pass metabolism of cyclosporin by the gut. Lancet 338, 1488-1490 (1991).
9. M. F. Hebert, J. P. Roberts, T. Prueksaritanont, and L. Z. Benet: Bioavailability of cyclosporine with concomittant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin. Pharmacol. Ther. 52, 453-457 (1992).
10. C. H. Walker: Species variations in some hepatic microsomal enzymes that metabolize xenobiotics. In "Progress in Drug Metabolism" (J. W. Bridges and L. F. Chasseaud, eds.), vol. 5, pp. 113-164. John Wiley & Sons, New York, 1980.
11. J. A. Boutin, B. Antoine, A.-M. Batt, and G. Siest: Heterogeneity of hepatic microsomal UDP-glucuronyltransferase(s) activities: comparison between human and mammalian species activities. Chem.-Biol. Interact. 52, 173-184 (1984).
12. H. S. Amri, A. M. Batt, and G. Siest: Comparison of cytochrome P-450 content and activities in liver microsomes of seven animal species, including man. Xenobiotica 16, 351-358 (1986).
13. S.-H. L. Chiu: The use of in vitro metabolism studies in the understanding of new drugs. J. Pharmacol. Toxicol. Methods 29, 77-83 (1993).
14. S. A. Wrighton, M. Vandenbranden, J. C. Stevens, L. A. Shipley, B. J. Ring, A. E. Rettie, and J. R. Cashman: In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab. Rev. 25, 453-484 (1993).
15. K. L. Andus, R. L. Bartel, I. J. Hidalgo, and R. T. Borchardt: The use of cultured epithelial and endothelial cells for drug transport and metabolism studies. Pharm. Res. 2, 435-451 (1990).
16. A. R. Hilgers, R. A. Conradi, and P. S. Burton: Caco-2 cell monolayer as a model for drug transport across the intestinal mucosa. Pharm. Res. 7, 902-910 (1990).
17. A. Buur and N. Mørk: Metabolism of testosterone during transport across Caco-2 cell monolayers: evidence for β-hydroxysteroid dehydrogenase activity in differentiated Caco-2 cells. Pharm. Res. 9, 1290-1294 (1992).
18. X. Boulenc, M. Bourrie, I. Fabre, C. Roque, H. Joyeux, Y. Berger, and G. Fabre: Regulation of cytochrome P4501A1 gene expression in a human intestine cell line, Caco-2. J. Pharmacol. Exp. Ther. 263, 1471-1478 (1992).
19. T. Sergent-Engelen, V. Delistrie, and Y.-J. Schneider: Phase I and II biotransformations in living Caco 2 cells cultivated under serum-free conditions: selective apical excretion or reaction products. Biochem. Pharmacol. 46, 1393-1401 (1993).
20. W. H. N. Peters and H. M. J. Roelofs: Time-dependent activity and expression of glutathione S-transferase in the human colon adenocarcinoma cell line Caco-2. Biochem. J. 264, 613-616 (1989).
21. S. Bjorge, K. L. Hamelehle, R. Homan, S. E. Rose, D. A. Turluck, and D. S. Wright: Evidence for glucuronide conjugation of p-nitrophenol in the Caco-2 cell model. Pharm. Res. 8, 1441-1443 (1991).
22. A. Baranczyk-Kuzma, J. A. Garren, I. J. Hidalgo, and R. T. Borchardt: Substrate specificity and some properties of phenol sulfotransferase from human intestinal Caco-2 cells. Life Sci. 49, 1197-1206 (1991).
23. A. Abid, I. Bouchon, G. Siest, and N. Sabolovic: Glucuronidation in the Caco-2 human intestinal cell line: induction of UDP-glucuronosyltransferase 1*6. Bicohem. Pharmacol. 50, 557-561 (1995).
24. P. J. Chikhale and R. T. Borchardt: Metabolism of L-α-methyldopa in cultured human intestinal epithelial (Caco-2) cell monolayers. Drug Metab. Dispos. 22, 592-600 (1994).
25. A. E. Cribb, C. Nuss, and R. Wang: Antipeptide antibodies against overlapping sequences differentially inhibit human CYP2D6. Drug Metab. Dispos. 23, 671-675 (1995).
26. R. M. Long, H. Satoh, B. M. Martin, S. Kimura, F. J. Gonzales, and L. R. Pohl: Rat liver carboxylesterase: cDNA cloning, sequencing and evidence for a multigene family. Biochem. Biophys. Res. Commun. 156, 866-873 (1988).
27. T. Prueksaritanont, L. M. Dwyer, and A. E. Cribb: (+)-Bufuralol 1′-hydroxylase activity in human and rhesus monkey intestine and liver. Biochem. Pharmacol. 50, 1521-1525 (1995).
28. T. Prueksaritanont, M. A. Correia, A. E. Rettie, D. C. Swinney, P. E. Thomas, and L. Z. Benet: Cyclosporine metabolism by rat liver microsomes: evidence for involvement of enzyme(s) other than cytochromes P450 3A. Drug Metab. Dispos. 21, 730-737 (1993).
29. U. M. Zanger, F. Vilbois, J. P. Hardwick, and U. A. Meyer: Absence of hepatic cytochrome P450bufl causes genetically deficient debrisoquine oxidation in man. Biochemistry 27, 5447-5454 (1988).
30. D. J. Newton, R. W. Wang and A. Y. H. Lu: Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23, 154-158 (1995).
31. M. D. Burke, S. Thompson, C. R. Elcombe, J. Halpert, T. Haaparanta, and R. T. Mayer: Ethoxy-, penthoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochrome P-450. Biochem. Pharmacol. 34, 3337-3345 (1985).
32. K. Krisch: Reaction of a microsomal esterase from hog-liver with diethyl p-nitrophenyl phosphate. Biochim. Biophys. Acta 122, 265-280 (1966).
33. R. Mentlein and E. Hyemann: Hydrolysis of ester- and amide-type drugs by the purified isoenzymes of nonspecific carboxylesterase from rat liver. Biochem. Pharmacol. 33, 1243-1248 (1984).
34. H. H. Andres, A. J. Klem, S. M. Szabo, and W. W. Weber: New spectrophotometric and radiochemical assays for aetyl-CoA:arylamine N-acetyltransferase applicable to a variety of arylamines. Anal. Biochem. 145, 367-375 (1985).
35. K. Chan, J. O. Miners, and D. J. Birkett: Direct and simultaneous high-performance liquid chromatographic assay for the determination of p-aminobenzoic acid and its conjugates in human urine. J. Chromatogr. 426, 103-109 (1988).
36. P. T. Reeves, R. F. Minchin, and K. F. Ilett: Induction of sulfamethazine acetylation by hydrocortisone in the rabbit. Drug Metab. Dispos. 16, 110-115 (1988).
37. W. H. Habig and W. B. Jakoby: Assays for differentiation of glutathione S-transferases. In "Methods in Enzymology," vol. 77, pp. 399-405. Academic Press, New York, 1981.
38. S. A Wrighton and J. C. Stevens: The human hepatic cytochromes P-450 involved in the drug metabolism. Crit. Rev. Toxicol. 22, 1-21 (1992).
39. J. C. Kolars, K. S. Lown, P. Schmiedlin-Ren, M. Ghosh, C. Fang, S. A. Wrighton, R. M. Merion, and P. B. Watkins: CYP3A gene expression in human gut epithelium. Pharmacogenetics 4, 247-259 (1994).
40. K. S. Lown, J. C. Kolars, K. E. Thummel, J. L. Barnett, K. L. Kunze, S. A. Wrighton, and P. B. Watkins: Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: lack of prediction by the erythromycin breath test. Drug Metab. Dispos. 22, 947-955 (1994).
41. P. B. Watkins, S. A. Wrighton, E. G. Schuetz, D. T. Molowa, and P. S. Guzelian: Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J. Clin. Invest. 80, 1029-1035 (1987).
42. M. Hosokawa, T. Maki and T. Satoh: Characterization of molecular species of liver microsomal carboxylesterases of several animal species and humans. Arch. Biochem. Biophys. 277, 219-227 (1990).
43. D. J. Waxman, C. Attisano, F. P. Guengerich, and D. P. Lapenson: Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6β-hydroxylase cytochrome P-450 enzyme. Arch. Biochem. Biophys. 263, 424-436 (1988).
44. F. M. Williams, E. M. Mutch, E. Nicholson, H. Wynne, P. Wright, D. Lambert, and M. D. Rawlins: Human liver and plasma aspirin esterase. J. Pharm. Pharmacol. 41, 407-409 (1989).
45. D. M. Grant, M. Blum, M. Beer, and U. A. Meyer: Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of human liver isozymes and expressed products of two cloned genes. Mol. Pharmacol. 39, 184-191 (1991).
46. E. W. Morgan, B. Yan, D. Greenway, D. R. Peterson, and A. Parkinson: Purification and characterization of two rat liver microsomal carboxylesterass (hydrolase A and B). Arch. Biochem. Biophys. 315, 495-512 (1994).
47. F. M. Williams: Clinical significance of esterases in man. Clin. Pharmacokinet. 10, 392-403 (1985).
48. M. Inoue, M. Morikawa, M. Tsuboi, and M. Sugiura: Species difference and characterization of intestinal esterase on the hydrolyzing activity of ester-type drugs. Jpn. J. Pharmacol. 29, 9-16 (1979).
49. L.-S. Gan, A. Moseley, B. Khosla, P. Augustijns, T. Bradshaw, W. Hendren, and D. Thakker: Formation and polarized efflux of cyclosporin A metabolites in the in vitro Caco-2 cell culture system. FASEB J. 9, A367 (1995).
50. V. Carriere, T. Lesuffleur, A. Barbat, M. Rousset, E. Dussaulx, P. Costet, I. de Waziers, P. Beaune, and A. Zweibaum: Expression of cytochrome P-450 3A in HT29-MTX cells and Caco-2 clone TC7. FEBS Lett. 355, 247-250 (1994).
51. C. J. Doecke, M. E. Veronese, S. M. and Pond, J. O. Miners, D. J. Birkett, L. N. Sansom, and M. E. McManus: Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br. J. Clin. Pharmacol. 31, 125-130 (1991).
52. J. E. Sharer, L. A. Shipley, M. R. VandenBranden, S. N. Binkley, and S. A. Wrighton: Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metab. Dispos. 23, 1231-1241 (1996).
53. J. C. Stevens, L. A. Shipley, J. R. Cashman, M. Vandenbranden, and S. A. Wrighton: Comparison of human and rhesus monkey in vitro phase I and phase II hepatic drug metabolism activities. Drug Metab. Dispos. 21, 753-760 (1993).
54. M. Hosokawa, T. Endo, M. Fujisawa, S. Hara, N. Iwata, Y. Satao, and T. Satoh: Interindividual variation in carboxylesterase levels in human liver microsomes. Drug. Metab. Dispos. 23, 1022-1027 (1995).
55. D. J. Ecobichon: Relative amounts of hepatic and renal carboxylesterase in mammalian species. Res. Commun, Chem. Pathol. Pharmacol. 3, 629-636 (1972).
56. F.-J. Leinweber: Possible physiological roles of carboxylic ester hydrolases. Drug Metab. Rev. 18, 379-439 (1987).
57. W. H. M. Peters, L. Kock, F. M. Nagengast, and P. G. Kremers: Biotransformation enzymes in human intestine: critical low levels in the colon. Gut 32, 408-412 (1991).
58. D. M. Grant, K. Morike, M. Eichelbaum, and U. A. Meyer: Acetylation pharmacogenetics: the slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J. Clin Invest. 85, 968-972 (1990).
59. D. Hickman, G. Chandrasena, and J. D. Unadkat: Longitudinal distribution of arylamine N-acetyltransferases along the human small intestine. ISSX Proc. 8, 250 (1995).
60. K. F. Ilett, D. M. Ingram, D. S. Carpenter, C. H. Teitel, N. P. Lang, F. F. Kadlubar, and R. F. Minchin: Expression of monomorphic and polymorphic N-acetyltransferases in human colon. Biochem. Pharmacol. 47, 914-917 (1994).
61. J. W. Rodriguez, W. G. Kirlin, R. J. Ferguson, M. A. Doll, K. Gray, T. D. Rustan, M. E. Lee, K. Kemp, P. Urso, and D. W. Hein: Human acetylator genotype: relationship to colorectal cancer incidence and arylamine N-acetyltransferase expression in colon cytosol. Arch. Toxicol. 67, 445-452 (1993).